10-Q: Supernus Pharmaceuticals Reports Q1 2025 Results: Qelbree Sales Surge, ONAPGO Launched
Quarterly Report
Supernus Pharmaceuticals' Q1 2025 results show increased revenue driven by Qelbree and GOCOVRI, offset by declines in other products, and the launch of ONAPGO.
Summary
- Supernus Pharmaceuticals reported a net loss of $11.8 million for Q1 2025, compared to a net income of $0.1 million in Q1 2024.
- Total revenue increased by 4% to $149.8 million, driven by Qelbree and GOCOVRI sales.
- Qelbree sales increased by 44% to $64.7 million, while GOCOVRI sales increased by 16% to $30.7 million.
- Oxtellar XR sales decreased by 62% to $10.2 million due to generic erosion.
- Research and development expenses increased to $26.9 million from $24.9 million.
- The company launched ONAPGO in April 2025, following FDA approval in February 2025.
- Total IQVIA prescriptions for Qelbree were 214,908 for the first quarter 2025, an increase of 22% compared to the same period in the prior year.
- For March 2025, total monthly prescriptions reached an all-time high of 75,277 for Qelbree.
- The company believes its balances of cash, cash equivalents, and unrestricted marketable securities, which totaled $463.6 million as of March 31, 2025, along with cash generated from ongoing operations and continued access to debt markets, will be sufficient to satisfy its cash requirements over the next 12 months and beyond.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, there are positive signs such as the strong growth of Qelbree and the launch of ONAPGO. However, the challenges of generic erosion and ongoing litigation temper the overall outlook.
Positives
- Qelbree continues to show strong growth, with a 44% increase in sales and a growing prescriber base.
- The launch of ONAPGO provides a new treatment option for Parkinson's disease patients.
- GOCOVRI sales increased by 16% year-over-year.
- The company has $463.6 million in cash, cash equivalents, and marketable securities, which is expected to be sufficient to meet cash requirements for the next 12 months and beyond.
Negatives
- The company reported a net loss of $11.8 million for Q1 2025.
- Oxtellar XR sales declined significantly due to generic erosion.
- Trokendi XR sales decreased by 20% year-over-year.
- Contingent consideration was a loss of $7.7 million for the three months ended March 31, 2025.
Risks
- The company faces market and payor pressures for its commercial products.
- The loss of patent exclusivity for Trokendi XR and Oxtellar XR is negatively impacting sales.
- The company is involved in ongoing litigation, including patent and antitrust cases.
- The company's future profitability is subject to variability due to market conditions, competition, and the success of its product candidates.
Future Outlook
The company expects continued profitability but anticipates significant variability due to market pressures, loss of patent exclusivity, funding for R&D, and the launch of ONAPGO. The company may consider raising additional capital through collaborative arrangements, strategic alliances, or additional equity and/or debt financings.
Management Comments
- Initial physician response is encouraging based on very early activity in the launch of ONAPGO.
Industry Context
Supernus operates in the competitive CNS pharmaceutical market, facing generic erosion for some products while launching new innovative treatments like ONAPGO. The company's focus on ADHD, Parkinson's disease, and epilepsy aligns with significant unmet needs in these therapeutic areas.
Comparison to Industry Standards
- Supernus's Qelbree competes with stimulant and non-stimulant ADHD medications from companies like Eli Lilly (Strattera) and Shire (Adderall XR).
- ONAPGO competes with other apomorphine formulations and delivery methods for Parkinson's disease, such as those from AbbVie and Teva.
- The generic erosion of Oxtellar XR is a common challenge faced by pharmaceutical companies when patents expire, similar to what Teva and Mylan have experienced with their generic versions of branded drugs.
Legal Proceedings
- Supernus is involved in patent litigation related to Trokendi XR, including cases against Ajanta Pharma and Torrent Pharmaceuticals.
- Supernus is involved in antitrust litigation related to APOKYN, including a case filed by Sage Chemical, Inc. and TruPharma, LLC.
- Adamas is involved in a qui tam litigation related to NAMENDA XR and Namzaric.
Stakeholder Impact
- Shareholders may be concerned about the net loss reported for Q1 2025.
- Employees may be affected by the company's efforts to manage costs and navigate market challenges.
- Patients may benefit from the launch of new treatments like ONAPGO.
- Suppliers and vendors may be impacted by the company's efforts to mitigate cost increases.
Next Steps
- The Company plans to initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD).
- The Company expects to disclose a lead indication for the SPN-443 product candidate by the end of 2025.
Key Dates
| Date | Description |
|---|---|
| April 2019 | MDD Subsidiaries entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services which was effective in April 2019. |
| April 2020 | The Company entered into a development agreement with Navitor Pharmaceuticals, Inc. |
| November 24, 2021 | The Company completed its acquisition of all the outstanding equity of Adamas (Adamas Acquisition). |
| January 1, 2023 | The Company entered into settlement agreements that allowed third parties to enter the Trokendi XR market. |
| February 8, 2023 | The Company entered into a credit line agreement with UBS. |
| September 2024 | The Company entered into settlement and license agreements that allowed a third party to enter the Oxtellar XR market. |
| November 2024 | ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220) The new standard, issued in November 2024, requires additional disclosure in tabular format, about the nature of specific types of expense captions presented on the face of the income statement as well as disclosures about selling expenses. |
| December 2027 | The Company entered into settlement and license agreements that allows third parties to enter the XADAGO market in December 2027, or sooner under certain conditions. |
| February 2025 | The FDA approved ONAPGO (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. |
| February 2025 | The Company reported topline results from a randomized double-blind placebo-controlled Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD). |
| April 2025 | ONAPGO was launched. |
| April 2025 | The Company received an official notification of release from the Office of the Inspector General and thus no longer remains subject to its obligations under the CIA. |
Keywords
Supernus Pharmaceuticals, Qelbree, ONAPGO, GOCOVRI, Oxtellar XR, Trokendi XR, ADHD, Parkinson's Disease, Epilepsy, Financial Results, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.